Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 10/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5776524 | 0.84 | EPHX2 (0.43) | SLC6A4SLC6A3POLB | |
| SCHEMBL5777386 | 0.83 | LMNA (0.47) | ALDH1A1KMT2APOLB | |
| SCHEMBL5774072 | 0.81 | LMNA (0.54) | ALDH1A1HPGDKMT2ARAB9APOLB | |
| SCHEMBL5773900 | 0.80 | CYP1A2 (0.52) | ALDH1A1HPGDKMT2ARAB9ASLC6A4 | |
| SCHEMBL5773998 | 0.79 | FFAR1 (0.46) | ALDH1A1HPGDPOLBTSHR | |
| SCHEMBL5771249 | 0.79 | RAB9A (0.51) | ALDH1A1HPGDKMT2ARAB9APOLB | |
| SCHEMBL5773717 | 0.78 | L3MBTL1 (0.52) | ALDH1A1HPGDKMT2ARAB9ASLC6A4 | |
| SCHEMBL5769962 | 0.78 | SMN1; SMN2 (0.41) | ALDH1A1HPGDKMT2ARAB9A | |
| SCHEMBL5771183 | 0.78 | ROCK2 (0.45) | ALDH1A1KMT2APOLB | |
| SCHEMBL5772947 | 0.78 | MGLL (0.47) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | SLC6A9 930/4885ALDH1A1 1045/4885HPGD 1588/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | SLC6A9 713/4885ALDH1A1 682/4885HPGD 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.